Woman and Man | 65 years and more
- | Country :
- France
- | organs :
- Myélomes
- | Specialty :
- Chimiothérapie
- Gériatrie
Extract
A phase III, randomized, open-label, 3-arm study to determine the efficacy and safety of lénalidomide (REVLIMID) plus low-dose dexamethasone when given until progressive disease or for 18 four-week cycles versus the combination of melphalan, prednisone, and thalidomide given for 12 six-week cycles in patients with previously untreated multiple myeloma who are either 65 years of age or older or not candidates for stem cell transplantation.
Scientific Abstract
en cours d'intégration;